重大事件即時報告 8-K 2026-07-30

Tevogen Bio Holdings 更名為 Tevogen Inc. 8-K 申報生效

AI 繁中摘要

8-K 申報摘要｜Tevogen Bio Holdings Inc. 更名為 Tevogen Inc.

📄 申報類型：8-K（重大事件報告）
📅 報告日期：2026年7月29日｜生效日期：2026年7月30日

Tevogen Bio Holdings Inc.（以下簡稱「公司」）於2026年7月29日向美國證券交易委員會（SEC）提交8-K表格，披露公司名稱正式變更。公司已向 Delaware 州政府提交修訂證書，將名稱由「Tevogen Bio Holdings Inc.」改為「Tevogen Inc.」，新名稱於2026年7月30日生效。

為配合更名，公司董事會亦通過相應修訂，更新了《經修訂及重述的公司章程細則》中的公司名稱，其他條款維持不變。

🔑 重點細節：
- 公司普通股及公開認股權證繼續在納斯達克全球市場交易，股票代碼均維持不變：普通股為「TVGN」，認股權證為「TVGNW」。
- CUSIP 編號亦無變動：普通股為 88165K200，公開認股權證為 88165K119。
- 是次更名不影響股東的任何權利或公司證券的條款。

💡 對投資者的潛在影響：
更名純屬公司品牌及識別更新，並未涉及業務、財務狀況或股東權益的實質變化。流通股份數目、股票代碼及 CUSIP 均維持不變，投資者無需採取任何行動。市場反應或會短暫關注品牌重塑，但基本面前景並無因更名而改變。

📎 附件：修訂證書（Exhibit 3.1）及經修訂章程細則（Exhibit 3.2）。

展開英文正文

false
 --12-31
 0001860871
 
 
 
 
 
 
 
 0001860871
 
 
 2026-07-29
 2026-07-29
 
 
 
 
 0001860871
 
 TVGN:CommonStockParValue0.001PerShareMember
 
 
 
 2026-07-29
 2026-07-29
 
 
 
 
 0001860871
 
 TVGN:WarrantsExercisableFor575PerShareOfCommonStockMember
 
 
 
 2026-07-29
 2026-07-29
 
 
 
 iso4217:USD
 
 
 xbrli:shares
 
 
 
 
 iso4217:USD
 
 
 xbrli:shares
 
 
 
 
 

 

 

 

UNITED
STATES

SECURITIES
AND EXCHANGE COMMISSION

WASHINGTON,
D.C. 20549

 

 

 

FORM
8-K

 

 

 

CURRENT
REPORT

Pursuant
to Section 13 or 15(d)

of
the Securities Exchange Act of 1934

 

Date
of Report (Date of earliest event reported): July 29, 2026

 

 

 

Tevogen Bio Holdings Inc. 

Tevogen
Inc.

(Exact
name of Registrant as Specified in Its Charter)

 

 

 

 
 Delaware
  
 001-41002
  
 98-1597194

 
 (State
 or Other Jurisdiction

 of Incorporation)
  
 (Commission

 File
 Number)

  
 (IRS
 Employer

 Identification No.)

 
 

 
 15
 Independence Boulevard, Suite #210
  
  

 
 Warren,
 New Jersey
  
 07059

 
 (Address
 of Principal Executive Offices)
  
 (Zip
 Code)

 
 

Registrant’s
Telephone Number, Including Area Code: (877) 838-6434

 

Tevogen
Bio Holdings Inc.

(Former
Name or Former Address, if Changed Since Last Report)

 

 

 

Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:

 

 
 ☐
 Written
 communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 
  
  

 
 ☐
 Soliciting
 material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 
  
  

 
 ☐
 Pre-commencement
 communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 
  
  

 
 ☐
 Pre-commencement
 communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 
 

Securities
registered pursuant to Section 12(b) of the Act:

 

 
 Title
 of each class
  
 Trading
 Symbol(s)
  
 Name
 of each exchange on which registered

 
 Common
 Stock, par value $0.001 per share
  
 TVGN
  
 The
 Nasdaq Global Market

 
 Warrants,
 exercisable for $575 per share of Common Stock
  
 TVGNW
  
 The
 Nasdaq Global Market

 
 

Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

 

Emerging
growth company ☐

 

If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

  

  

 

 

 
 Item
 5.03
 Amendments
 to Articles of Incorporation or Bylaws; Change in Fiscal Year. 

 
 

On
July 29, 2026, Tevogen Bio Holdings Inc. (the “Company”) filed a certificate of amendment (the “Certificate of Amendment”)
to its Certificate of Incorporation, as amended, solely to change the Company’s name from “Tevogen Bio Holdings Inc.”
to “Tevogen Inc.” The name change became effective on July 30, 2026. A copy of the Certificate of Amendment is attached hereto
as Exhibit 3.1 and incorporated herein by reference.

 

In
connection with the name change, the Company’s Board of Directors approved an amendment (the “Bylaws Amendment”) to
the Company’s Amended and Restated Bylaws (the “Bylaws”), to reflect the change in the Company’s name, also effective
July 30, 2026. No other changes were made to the Bylaws. A copy of the Bylaws, as amended by the Bylaws Amendment, is attached as Exhibit
3.2 hereto and incorporated herein by reference.

 

The
Company’s common stock and public warrants continue to trade on the Nasdaq Global Market under the ticker symbols “TVGN”
and “TVGN”, respectively.

 

The
name change does not affect the rights of the Company’s security holders and the CUSIP numbers for the Company’s common stock
and public warrants will continue to be 88165K200 and 88165K119, respectively.

 

 
 Item 9.01
 Financial
 Statements and Exhibits. 

 
 

(d)
Exhibits.

 

 
 Exhibit

 No.

  
 Description

 
  
  

 
 3.1
  
 Certificate of Amendment to Certificate of Incorporation

 
 3.2
  
 Amended and Restated Bylaws

 
 104
  
 Cover
 Page Interactive Data File (embedded within the Inline XBRL document)

 
 

  

  

 

 

SIGNATURES

 

Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.

 

 
  
 TEVOGEN INC.

 
  
  
  

 
 Date:
 July 30, 2026
 By:
 /s/
 Ryan Saadi

 
  
  
 Ryan
 Saadi

 
  
  
 Chief
 Executive Officer